

# Anthony B Costales

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9253218/publications.pdf>

Version: 2024-02-01

12  
papers

91  
citations

1478505

6  
h-index

1474206

9  
g-index

12  
all docs

12  
docs citations

12  
times ranked

57  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2022, 40, 100951.	0.6	2
2	Postoperative arterial thromboembolism resulting in acute limb ischemia after staging surgery for endometrial carcinoma: A case report. <i>Gynecologic Oncology Reports</i> , 2022, 41, 100983.	0.6	0
3	Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2021, 50, 101844.	1.3	5
4	Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 45-50.	1.4	12
5	Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer. <i>Gynecologic Oncology</i> , 2021, 161, 194-201.	1.4	8
6	Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Gynecologic Oncology</i> , 2021, 161, 389-395.	1.4	11
7	Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2021-002622.	2.5	4
8	Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Gynecologic Oncology</i> , 2021, 162, 368-374.	1.4	13
9	Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer. <i>Gynecologic Oncology</i> , 2021, 162, 645-651.	1.4	8
10	Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100876.	0.6	2
11	A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology. <i>Gynecologic Oncology</i> , 2020, 158, 794-802.	1.4	21
12	Characterizing the efficacy and trends of adjuvant therapy versus observation in women with early stage (uterine confined) leiomyosarcoma: a National Cancer Database study. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e21.	2.2	5